Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study
Advances in Therapy · 2024-07 · 41 (7) · 2978-2990
DOI: 10.1007/s12325-024-02889-8 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Advances in Therapy, online erschienen am 27.05.2024. Verfasst von Tara F Carr und 12 weiteren Autor:innen. Beteiligte Einrichtung: Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA. Hauptthemen laut MEDLINE: Asthma, Antibodies, Monoclonal, Humanized, Anti-Asthmatic Agents. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, AstraZeneca, Amgen, Inc..
Abstract (Originalsprache)
INTRODUCTION: Many patients with severe asthma continue to experience symptoms and exacerbations despite treatment with standard-of-care therapy. In the phase 3 NAVIGATOR study, tezepelumab significantly reduced exacerbations over 52 weeks compared with placebo in patients with severe, uncontrolled asthma. This analysis assessed the efficacy of tezepelumab in reducing asthma exacerbations in various clinically relevant subgroups of patients in NAVIGATOR. METHODS: NAVIGATOR was a phase 3, multicentre, randomized, double-blind, placebo-controlled study. Participants (12-80 years old) with severe, uncontrolled asthma were randomized 1:1 to receive tezepelumab 210 mg or placebo subcutaneously every 4 weeks for 52 weeks. Pre-specified and post hoc analyses were performed to evaluate the annualized asthma exacerbation rate (AAER) over 52 weeks in clinically relevant subgroups of patients defined by baseline patient characteristics, medical history, exacerbation triggers, medication eligibility and medication use before and during the study. RESULTS: Tezepelumab reduced the AAER over 52 weeks compared with placebo across a wide range of patient subgroups assessed. Reductions in exacerbations were similar across subgroups defined by baseline patient characteristics, ranging from 48% (95% confidence interval [CI]: 21, 65) to 60% (95% CI: 44, 71) in subgroups analysed by sex, smoking history and body mass index. Among the asthma-related comorbidity subgroups investigated, patients with aspirin or NSAID sensitivity had the greatest reductions in AAER with tezepelumab compared with placebo (83%; 95% CI: 66, 91). In patients eligible to receive dupilumab, tezepelumab reduced exacerbations compared with placebo by 64% (95% CI: 54, 71). Reductions in the AAER with tezepelumab compared with placebo were also observed irrespective of exacerbation trigger category and the number of asthma controller medications patients were receiving at baseline. CONCLUSION: These findings further support the benefits of tezepelumab in patients with severe, uncontrolled asthma and can help to inform healthcare providers' treatment decisions. CLINICAL TRIAL REGISTRATION: NAVIGATOR (NCT03347279).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Asthma and Airway Disease Research Center, University of Arizona, Tucson, AZ, USA.
- Department of Internal Medicine, Section on Pulmonary, Critical Care, Allergy and Immunologic Diseases, Wake Forest School of Medicine, Winston-Salem, NC, USA.
- Department of Medicine, Icahn School of Medicine, Mount Sinai Health System, New York, NY, USA.
- Department of Respiratory Medicine, Ghent University Hospital, Ghent, Belgium.
- Division of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
- Yale Center for Asthma and Airway Disease, Yale School of Medicine, Yale University, New Haven, CT, USA.
ORCID-Profile: Andrew W Lindsley, Jean-Pierre Llanos, Christopher S Ambrose
Förderung
- NCATS NIH HHS
- AstraZeneca
- Amgen, Inc.
Zitieren
APA
Carr, T. F., Moore, W. C., Kraft, M., Brusselle, G., Castro, M., Chupp, G. L., Wechsler, M. E., Hunter, G., Lindsley, A. W., Llanos, J. P., Burke, L. K., Chandarana, S., & Ambrose, C. S. (2024). Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances in Therapy, 41(7), 2978-2990. https://doi.org/10.1007/s12325-024-02889-8
Vancouver
Carr TF, Moore WC, Kraft M, Brusselle G, Castro M, Chupp GL, et al. Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study. Advances in Therapy. 2024;41(7):2978-2990. doi:10.1007/s12325-024-02889-8
BibTeX
@article{Carr2024,
author = {Carr, Tara F and Moore, Wendy C and Kraft, Monica and Brusselle, Guy and Castro, Mario and Chupp, Geoffrey L and Wechsler, Michael E and Hunter, Gillian and Lindsley, Andrew W and Llanos, Jean-Pierre and Burke, Luke K and Chandarana, Shradha and Ambrose, Christopher S},
title = {Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study},
journal = {Advances in Therapy},
year = {2024},
volume = {41},
number = {7},
pages = {2978--2990},
doi = {10.1007/s12325-024-02889-8}
}
EUVIMED